ATOS

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).

Wall Street analysts forecast ATOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATOS is 6.25 USD with a low forecast of 4.00 USD and a high forecast of 7.75 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Atossa Therapeutics Inc revenue for the last quarter amounts to -9.25M USD, increased 44.89 % YoY.

Atossa Therapeutics Inc. EPS for the last quarter amounts to -6012000.00 USD, increased 26.30 % YoY.

Atossa Therapeutics Inc (ATOS) has 13 emplpoyees as of January 10 2026.

Today ATOS has the market capitalization of 83.33M USD.